Literature DB >> 12099924

Cerebral vasospasm and ischaemic infarction in clipped and coiled intracranial aneurysm patients.

M Hohlrieder1, M Spiegel, J Hinterhoelzl, K Engelhardt, B Pfausler, A Kampfl, H Ulmer, P Waldenberger, I Mohsenipour, E Schmutzhard.   

Abstract

The influence of the treatment modalities (clipping/coiling) on the incidence of vasospasm and ischaemic infarction in aneurysm patients is still judged controversially. The purpose of this study was to analyse and compare retrospectively cerebral vasospasm and ischaemic infarction, as well as neurological deficits and outcome within a large population of clipped and coiled patients with ruptured and unruptured aneurysms. Within a 2-year period, a total of 144 interventions (53 clipping/91 coiling) entered the study. Daily bilateral transcranial Doppler sonographic monitoring was performed to observe vasospasm development. All cerebral computed tomography (cCT) and magnetic resonance imaging (MRI) scans were reviewed with respect to occurrence and localization of ischaemic infarctions. Focal neurological deficits were recorded and clinical outcome was evaluated using the Glasgow Outcome Scale. Statistical analysis included the use of multivariate logistic regression models to find determinants of vasospasm, ischaemic infarction and neurological deficits. Altogether, vasospasm was detected after 77 (53.5%) interventions, 61.8% in females (P < 0.01). Clipped patients significantly more often exhibited vasospasms (69.8 vs. 44.0%, P < 0.005) and were treated 1 week longer at the intensive care unit (P < 0.005). Seventy-seven patients (53.5%) developed ischaemic infarctions, 62.3% after clipping and 48.4% after coiling (P > 0.05). In the multivariate analysis, aneurysm-rupture was the strongest predictor for vasospasm and vasospasm was the strongest predictor for infarction. Neurological deficits at discharge (46.5%) were independent of treatment modality, the same applied for the mean Glasgow Outcome Scores. There was no significant difference in mortality between surgical and endovascular treatment (9.4 vs. 12.1%). Whilst the vasospasm incidence was significantly higher after surgical treatment, ischaemic infarctions were only slightly more frequent. The incidence of neurological deficits and clinical outcome was similar in both treatment groups.

Entities:  

Mesh:

Year:  2002        PMID: 12099924     DOI: 10.1046/j.1468-1331.2002.00425.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

1.  Prevalence, timing, risk factors, and mechanisms of anterior cerebral artery infarctions following subarachnoid hemorrhage.

Authors:  Michael Moussouttas; Torrey Boland; Lily Chang; Ameesh Patel; Jaime McCourt; Mitchell Maltenfort
Journal:  J Neurol       Date:  2012-06-24       Impact factor: 4.849

2.  Cerebrovasospasm following endoscopic cerebrospinal fluid leak repair.

Authors:  Jason P Hunt; Trent Richards
Journal:  Skull Base       Date:  2010-09

3.  Focal laminar cortical infarcts following aneurysmal subarachnoid haemorrhage.

Authors:  Stefan Weidauer; Hartmut Vatter; Jürgen Beck; Andreas Raabe; Heinrich Lanfermann; Volker Seifert; Friedhelm Zanella
Journal:  Neuroradiology       Date:  2007-10-06       Impact factor: 2.804

4.  An Approach for Incorporating Context in Building Probabilistic Predictive Models.

Authors:  Juan Anna Wu; William Hsu; Alex At Bui
Journal:  Proc IEEE Int Conf Healthc Inform Imaging Syst Biol       Date:  2012-12-03

5.  Magnetic Resonance Imaging in Aneurysmal Subarachnoid Hemorrhage: Current Evidence and Future Directions.

Authors:  Sarah E Nelson; Haris I Sair; Robert D Stevens
Journal:  Neurocrit Care       Date:  2018-10       Impact factor: 3.210

6.  Outcomes of ruptured intracranial aneurysms treated by microsurgical clipping and endovascular coiling in a high-volume center.

Authors:  S K Natarajan; L N Sekhar; B Ghodke; G W Britz; D Bhagawati; N Temkin
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-09       Impact factor: 3.825

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.